Repurposing Valsartan May Protect Against Pulmonary Hypertension — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Repurposing Valsartan May Protect Against Pulmonary Hypertension — Stella

Home/Pulmonary Arterial Hypertension/

View on ClinicalTrials.gov

Recruiting

Back to Pulmonary Arterial Hypertension trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

University of Washington Medical Center, Seattle, Washington

Key details

Phase

Safety & dosing

Sponsor

University of Washington

Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Enrollment target

~60 participants

Started

February 2024

Primary completion

July 2027

Age range

18 Years – 80 Years

Last updated March 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.